Haleon plc (NYSE:HLN) is a prominent player in the consumer healthcare sector, known for its wide range ofhealth and wellness products. The company recently reported its half-year results for the first half of 2025 (HY2025, covering Q1 and Q2), revealing an adjusted earnings per share (EPS) of approximately £0.12, derived from an adjusted pretax profit of £1.11 billion, up 11.1% from £1.00 billion in HY 2024.
Revenue for the periodwas £5.48 billion, down 3.8% from £5.69 billion in HY 2024, primarily due to a 2.9% negative impact from mergers and acquisitions (M&A) and weaker demand in North America. On an organic basis, revenue grew by 3.2%, though this lagged the company-compiled consensus of 3.4%. The company also declared a 10% increase in the interim dividend to 2.2 pence per share, reflecting its policy to distribute approximately one-third of the prior year’s full-year dividend.
During the HY 2025 earnings Q&A conference, held on July 31, 2025, key figures such as CEO Brian McNamaraand CFO Dawn Amanda Allen provided insights into the company’s financial performance. The conference highlighted challenges in North America, including a 0.4% decline in organic revenue due to a weak consumerand retail environment, offset by strong organic revenue growth of 5.2% in Europe, Middle East, Africa & Latin America, and 5.0% in Asia-Pacific. The Oral Health segment, contributing 32% of revenue, led with 7.6% organic sales growth to £1.73 billion from £1.68 billion in HY 2024.
The company also launched a second tranche of share buybacks worth up to £260 million, part of a £500 million program for 2025. Haleon’s financial metrics offer a deeper understanding of its market position. The company has a price-to-earnings (P/E) ratio of approximately 22.11, indicating how the market values its earnings. The price-to-sales ratio is about 2.82, reflecting the market value relative to sales, while the enterprise value to sales ratio stands at around 3.52, providing insight into the company’s valuation, including debt. The company’s earnings yield is approximately 4.52%, offering a perspective on the return on investment for shareholders. With a debt-to-equity ratio of about 0.62, Haleon maintains a moderate level of debt relative to its equity, suggesting a balanced financial structure. Additionally, the current ratio of approximately 0.98 indicates the company’s ability to cover its short-term liabilities with its short-term assets, showcasing its financial stability
